Altium Capital Management LP bought a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 62,317 shares of the biotechnology company’s stock, valued at approximately $2,421,000. Altium Capital Management LP owned approximately 0.15% of REGENXBIO as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently bought and sold shares of the company. UBS Group AG boosted its position in REGENXBIO by 9.0% during the first quarter. UBS Group AG now owns 484,004 shares of the biotechnology company’s stock worth $16,509,000 after purchasing an additional 40,167 shares in the last quarter. Northern Trust Corp boosted its position in REGENXBIO by 12.3% during the first quarter. Northern Trust Corp now owns 438,745 shares of the biotechnology company’s stock worth $14,966,000 after purchasing an additional 48,013 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of REGENXBIO by 15.2% in the first quarter. Principal Financial Group Inc. now owns 256,060 shares of the biotechnology company’s stock valued at $8,734,000 after acquiring an additional 33,858 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of REGENXBIO by 83.2% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 76,645 shares of the biotechnology company’s stock valued at $2,614,000 after acquiring an additional 34,801 shares in the last quarter. Finally, Perceptive Advisors LLC purchased a new stake in shares of REGENXBIO in the first quarter valued at $2,363,000. Institutional investors own 77.85% of the company’s stock.
RGNX has been the topic of several recent research reports. Zacks Investment Research downgraded REGENXBIO from a “hold” rating to a “strong sell” rating in a research report on Friday, August 13th. Royal Bank of Canada upped their price objective on REGENXBIO from $50.00 to $55.00 and gave the company a “sector perform” rating in a research report on Tuesday, September 14th. Barclays upped their price objective on REGENXBIO from $79.00 to $82.00 and gave the company an “overweight” rating in a research report on Tuesday, September 14th. SVB Leerink restated a “hold” rating on shares of REGENXBIO in a research report on Tuesday. Finally, Chardan Capital reiterated a “buy” rating and set a $100.00 target price on shares of REGENXBIO in a research report on Tuesday, August 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $60.63.
REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Monday, August 9th. The biotechnology company reported ($1.36) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.08) by ($0.28). The firm had revenue of $22.04 million for the quarter, compared to analyst estimates of $21.17 million. REGENXBIO had a negative return on equity of 31.31% and a negative net margin of 90.05%. The business’s revenue was up 33.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.91) earnings per share. Research analysts expect that REGENXBIO Inc. will post -2.88 EPS for the current year.
In other REGENXBIO news, CEO Kenneth T. Mills sold 1,500 shares of the stock in a transaction that occurred on Monday, September 27th. The stock was sold at an average price of $42.19, for a total transaction of $63,285.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Allan M. Fox sold 48,233 shares of the firm’s stock in a transaction that occurred on Friday, September 17th. The shares were sold at an average price of $45.04, for a total value of $2,172,414.32. The disclosure for this sale can be found here. Corporate insiders own 12.40% of the company’s stock.
REGENXBIO, Inc is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors; and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381.
Featured Article: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?
Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for REGENXBIO Inc. (NASDAQ:RGNX).
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.